Ipozumax

Itraconazole, the active ingredient in Ipozumax, is a azole antifungal presented as an oral formulation for oral use. It treats systemic and superficial mycoses in adult patients requiring prescription therapy.

GNH USA supplies Ipozumax as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to manage fungal infections that affect various organ systems. - Systemic mycoses: effective in treating blastomycosis, histoplasmosis and aspergillosis by eradicating the causative fungi. - Superficial mycoses: resolves dermatophytosis and onychomycosis, improving skin and nail health. - Candidiasis: controls invasive Candida infections, reducing fungal burden and preventing dissemination.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: intermittent discomfort in the upper abdomen. - Rash: skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe visual disturbances: blurred vision or photophobia.

Itraconazole requires careful monitoring to ensure safe use. - Liver monitoring: assess hepatic function before and during therapy. - Cardiac assessment: avoid in patients with existing heart failure. - Drug interaction review: evaluate concomitant medications for CYP3A4 effects. - Pregnancy consideration: use only if benefits outweigh potential risks. - Storage: Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Itraconazole interacts with several drug classes and may alter their effectiveness.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing itraconazole levels. - Carbamazepine: strong enzyme inducer, markedly decreasing exposure. - Ketoconazole: competitive inhibition may increase toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: efficacy may be reduced, consider backup method. - Calcium channel blockers (e.g., verapamil): may increase itraconazole concentrations.